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Abstract (80 words)
Radiation therapy is rapidly evolving toward the delivery of higher dose rates to improve cancer
treatment. In vitro experiments were performed to investigate the response of 9L and MCF-7 cancer cell
lines, exposed to 10 MV X-ray radiations. Up to 8 Gy was delivered at a dose-rate of 50 cGy/min
compared to 5 Gy/min. The data obtained emphasizes the importance of taking into account not only the
physical, but also the radiobiological parameters, when planning a particular cancer treatment.
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1. Introduction
Radiation therapy (RT) is an important modality for many cancer treatments, with over 50% of
cancer patients receiving some form of RT as part of their cancer management plan. The ongoing
challenge in RT treatment is the controlled delivery of a lethal dose to the tumor whilst minimizing
damage to the surrounding normal tissue. Modern radiotherapy techniques such as intensity
modulation radiation therapy (IMRT), intensity modulated arc therapy (IMAT) or volumetricmodulated arc therapy (VMAT), and stereotactic radiotherapy (SRT) (Benedict et al. 2001; Siochi
1999; Tubiana et al. 2000) have improved local tumor control through better precision of the radiation
dose delivered. These technologies consequently often deliver more complex treatment fields than
conventional techniques.
Clinically, IMRT has become an important modality and it has been widely used in
radiotherapy for over 15 years. The capabilities of IMRT have been extensively described in the
literature in physical term advantages, such as target coverage conformity, better dose uniformity, and
sparing the adjacent normal tissue. These make IMRT superior to conventional or three-dimensional
conformal external radiotherapy (3D-CRT) (Cheung 2006; Intensity Modulated Radiation Therapy
Collaborative Working Group 2001). However, in IMRT, an increased number of monitor units
(MU’s) are required, and thus IMRT (beam-on time) generally involves a longer dose delivery time
than conventional RT. The radiobiological advantages of IMRT have been extensively debated in the
literature (Fowler et al. 2004; Ling et al. 2010; Lohse et al. 2011; Moiseenko et al. 2007; Mu et al.
2003; Sorensen et al. 2011; Wang et al. 2003). The suspicion that IMRT could decrease tumor control
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due to the increase in the overall treatment time does not have any clinical evidence, and is offset by
the advantages linked to the better conformation of physical doses to the target volumes and therefore
better sparing of critical organs.
Improvement in clinical outcomes can be achieved by reducing patient intra fraction
movements. Recent technical developments have therefore focused on increasing the clinical dose rates
to minimize the effect of such movements. Increasing the dose rate also has the added benefit of
reducing the overall patient treatment time thus allowing an increase in patient throughput. One recent
development is the removal of flattening filters in the linear accelerator heads (flattening filter free
(FFF) LINAC configuration), which has proven to be particularly beneficial for IMRT and SRT (Fu et
al. 2004; Kragl et al. 2009; Stathakis et al. 2009). The absence of the flattening filter, leading to a
significant decrease in the number of MU’s for a given photon treatment delivery, has been reported in
the literature for both Varian (energies 6 MV and 18 MV) (Stathakis et al. 2009) and Elekta (energies
6 MV and 10 MV) (Kragl et al. 2009) clinical linear accelerators. It is thus important to, and would be
hazardous not to, investigate the biological effectiveness of physical radiation doses delivered with
differing dose rates.
Some recent data published related to this has emphasized the radiobiological effect of a high
instantaneous dose rate and indicated that there is no effect of the instantaneous dose rate of FFF
LINACs on clonogenic cell survival (Sorensen et al. 2011). Other data however e.g. Lohse et al.
(2011), shows that the radiobiological effect of the FFF beam is dependent on the dose per pulse and
suggests that this might become a crucial factor that influences cancer cell survival. Ling et al. (2010)
reviewed the dose rate effect in external beam radiotherapy and concluded that it is the overall beamon time that determines the tumor cell survival, not the average dose-rate of the linear accelerator
(LINAC) nor the instantaneous dose-rates within LINAC pulses. In this work, we are primarily focused
on the overall time of irradiation and its influence on the survival of two cell lines with significantly
different radiosensitivities.
Dose-rate sparing is usually known to involve a decreased biological response to radiation
exposure at a low dose rate compared to a high dose rate, as theoretically predicted by Lajtha et al.
(1961). On the contrary, Mitchell et al. first identified the decrease in survival of HeLa cells irradiated
at a low dose rate of 37 cGy/h compared with a high dose rate of 1.54 Gy/h and this was referred to as
the “inverse dose-rate effect” (Mitchell et al. 1977; Mitchell et al. 1979b). Similar studies by Furre et
al. (1999), also observed an inverse dose-rate effect on NHIK 3025 cells. These data suggest that for
some cell lines, a monotonic increase in dose-rate does not produce a similar increase in cell killing.
Moreover, in some specific cell lines, increasing the dose rate actually decreases the cell killing
effectiveness.
In this article we report on results of in vitro experiments in which the biological effect of
differing dose-rates for 10 MV X-ray irradiations delivery from a LINAC has been assessed by colony
forming assay. The dose is delivered using clinical dose rates of 50 cGy/min compared to a 10-fold
higher dose rate of 5 Gy/min. 9L and MCF-7 cell lines were used because they represent a good preclinical model of brain and breast tumor tissues respectively. Their intrinsic radiosensitivity is
different, with 9L being considered to be more radiation resistant than the MCF-7. To our knowledge,
this is the first time that the biological effectiveness of 10 MV X-ray radiation doses on 9L and MCF-7
cell lines has been investigated. The significance in the findings of this study are discussed with regard
to observations on the radiosensitivity of the 9L and MCF-7 cells, concepts of radiobiology, and
potential implications for new methods of dose delivery (IMRT, IMAT, VMAT, etc.).
2. Material and Methods
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2.1. Cell lines
9L, an adherent, fibroblast-like, radio-resistant rat gliosarcoma cell line derived from Nnitrosomethylurea-induced tumor was obtained from the European Collection of Cell Cultures
(ECACC). MCF-7 is an adherent, epithelial-like, radiosensitive breast adenocarcinoma cell line
established from a 69-year-old female (American Type Culture Collection – ATCC). Both cell lines
were tested routinely for mycoplasma contamination. Cells were maintained in exponential growth in
DMEM (Invitrogen, AU) with L-Glutamine and supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Pen Strep) at 37C in a humidified incubator with 5% CO2 in air.
2.2. Irradiation procedures
The irradiations were performed at the radiation oncology department in the Prince of Wales hospital,
Randwick, Australia, using an Axesse Elekta LINAC with beam modulator (Elekta AB,
Kungstensgatan, Stockholm, Sweden) operated at energy of 10 MV. Single exposure with doses of 1,
2, 3, 5, and 8 Gy were delivered at dose rates of 50 cGy/min and 5 Gy/min.
Experiments were carried out with confluent cultures grown as monolayer in 12.5 cm2 cell culture
flasks with a vented screw cap (BD Falcon) containing 5 mL of DMEM medium and 30 mL of Hanks’
balanced salt solution (HBSS). The cells flasks were placed vertically facing the beam and were
positioned at a depth of 2.2 cm in solid water to match the Dmax depth of the 10 MV photon field. An
additional thickness of 10 cm of solid water was placed behind the flask to assure adequate scattering
conditions. To maintain electronic equilibrium conditions within the flasks during the irradiation, the
flasks were also surrounded by solid water slabs. The irradiation field size used for all experiments was
10.4  10.4 cm2 and the source-to-surface distance (SSD) was 100 cm. Figure 1 shows a schematic
diagram of the setup for cellular irradiation. Cell culture flasks were irradiated at room temperature.
Unirradiated control samples were kept at room temperature in the control room (i.e at the same
condition as the irradiated samples – full of HBSS buffer and placed vertically) while the other samples
were irradiated in the LINAC bunker.

2.3. Clonogenic survival
Cell survival was measured by the colony-forming assay, i.e. the ability of a single cell to form
colonies in vitro (Puck et al. 1956). The method used in this study was derived from previous work
(Oktaria et al. 2015). Both the control and irradiated cells were plated immediately after the irradiation
experiments. The medium was removed and the confluent cells were washed gently with DPBS (Ca2+
and Mg2+ free), then detached using Trypsin-EDTA. The disassociated cells were counted with a
haemocytometer and seeded at low densities to achieve approximately 100 colonies after fifteen
doubling times into 100-mm tissue culture dishes (BD Falcon) containing 10 mL of complete cell
medium (i.e. DMEM containing L-Glutamine and supplemented with 10% (v/v) FBS and 1% (v/v)
PenStrep). Depending on the prescribed dose, each experiment involved a maximum of three cells
densities with triplicate dishes for each density. The numbers of cells plated per petri dish were
determined by preliminary experiments designed in order to determine the radiosensitivity of the cell
lines. The cells in petri dishes were then incubated to allow colonies to form at 37C humidified 5%
(v/v) CO2 cell culture incubator (HERACELL 150i). After fifteen doubling times, the colonies were
fixed and stained with a mixture solution of 25% (v/v) crystal violet (Sigma-Aldrich) and 75% (v/v)
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ethanol for 5 minutes, washed, and air-dried. Only the numbers of colonies containing more than 50
cells were counted as observed by microscope.
2.2 cm thick of solid water

10 MV x-ray beam
10 cm thick of solid
water

SSD100
(10.4  10.4cm2 field size)

Table couch
T12.5cm2 flask (monolayer cells with
5mL cell medium + 30mL buffer) – side
view
Fig 1. Experimental setup for cellular irradiation.

2.4. Cell cycle analysis by flow cytometry
Measurements of the cell cycle distribution were performed by flow cytometric analysis using
propidium iodide (PI) staining. The method used was derived from previous work (Oktaria et al. 2015;
Vine et al. 2007). Cells (2.0 x 106) were centrifuged at 1500 rpm for 5 min at 4C and washed twice
with cold phosphate buffer solution (PBS) (Ca2+ and Mg2+ free) then fixed by drop wise addition of
1mL ice-cold ethanol (70%) and stored at -20C for up to 7 days before DNA analysis. The ethanol
was then removed via a centrifuge process, washed twice with cold PBS. The cells were then stained
with a solution containing 40 g/mL PI, 100 g/mL RNase A, and PBS (pH 7.4) at 37C for 1 hour.
The stained nuclei were analyzed for DNA-PI fluorescence using a Becton Dickinson fluorescenceactivated cell sorting (FACS) flow cytometer (BD LSR II; BD Biosciences, USA). A minimum of
10,000 single cell events was analyzed for each sample in each experiment and at least three
independent experiments was performed.
2.5. Data analysis
2.5.1. Plating efficiency and surviving fraction. The plating efficiency (PE) was calculated as the
number of surviving colonies divided by the number of cells seeded and the surviving fraction (SF) is
the cell survival fraction at dose, D is detailed in (Franken et al. 2006) The radiation dose-survival
curves were generated by plotting the SF as a function of the dose delivered on a semi-logarithmic
scale. The SF expressed as a function of dose (D) curves were fitted using IgorPro software using the
linear quadratic (LQ) model

where  [Gy-1] and  [Gy-2] are the

radiosensitivity parameters (Chadwick et al. 1973; Curtis 1986; Fertil et al. 1981; 1985; Franken et al.
2013).
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2.5.2. Flow cytometry data. Cell doublets and aggregates were gated out using a two-parameter
histogram of FL2-Area versus FL2-Height. The resulting DNA distribution was then analyzed on the
basis of histograms using FACSDiva software (V6.1.3; BD Biosciences, USA) for the proportion of
cells in G0/G1, S and G2/M phases of cell cycle. All data were stored by the computer system in a flow
cytometer standard (FCS) format.
3. Results
The cell survival curves of the 9L and MCF-7 cells after irradiation with 10 MV X-rays at a dose-rate
of 5 Gy/min are plotted on the same graph to allow comparison of the relative radiosensitivities of the
two cell lines (Figure 2). From the graph it can be seen that 9L cells are about 2.2 times more resistant
than MCF-7 cells. The 10% survival doses (D10) in 9L and MCF-7 are 8 Gy and 3.7 Gy, respectively.
Table 1 presents the radiobiological parameters and indicates that the 9L cell line is more radioresistant
than MCF-7. These findings are consistent with values published in the literature, which are
=0.24 Gy-1; =0.029 Gy-2 for glioblastomas and =0.45 Gy-1 and =0.039 Gy-2 for adenocarcinoma
(Malaise et al. 1987).

Fig 2. Survival curves of 9L and MCF-7 irradiated at a dose-rate of 5 Gy/min. The data were fitted to
the linear-quadratic model. The error bars represent the means SEM of at least three independent
experiments.
The results for the 10 MV X-rays irradiation experiment at a dose-rate of 50 cGy/min compared to
5 Gy/min on 9L and MCF-7 cells are shown in Figure 3. The reduction of dose-rate appears to have no
effect on clonogenic survival of 9L cells (Figure 3A). However, with MCF-7 cells, the lower dose-rate
irradiation results in a decreased clonogenic survival (Figure 3B). Analysis of the data using the LQ
model is shown in table 1 and reveals that the  value for MCF-7 cells irradiated at 50 cGy/min
(0.83 0.01 Gy-1) is larger than the corresponding value when irradiated at 5 Gy/min (0.47 0.03 Gy-1).
Hence, the change in the efficacy of treatments was found, as measured quantitatively by a significant
reduction of 20% in the necessary absorbed radiation dose in order to achieve the same 10% cellsurviving fraction. The relative biological effectiveness (RBE) was estimated from and  parameters
as the ratio of dose of the reference radiation (dose rate of 5 Gy/min) to that of the test radiation (dose
rate of 50 cGy/min) required to reduce the cell survival to 37%. The calculated RBE values were 1 and
1.5 for 9L and MCF-7, respectively.
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In an effort to evaluate whether the observed inverse dose-rate effect is linked to the proportion of cells
in radioresistant and sensitive phases of the cell cycle, FACS analysis was performed. Under
asynchronous confluent conditions, the percentages of cells in G0/G1, S, and G2/M in both cell lines are
summarized in Table 2.
(A)
(B)

Fig 3. Survival curves of 9L cells (Panel A) and MCF-7 cells (Panel B) irradiated at dose rate of 50
cGy/min vs. dose rate 5 Gy/min. The data were fitted to the linear quadratic model. Each data point
represents the means SEM of at least three independent experiments (each triplicate).

4. Discussions
Clonogenic assay was used to determine cell reproductive death after treatment with ionizing radiation
as described by Puck and Markus (1956) who obtained the first X-ray radiation dose survival curve for
irradiated HeLa cells in culture. Since their pioneering work, the intrinsic radiosensitivity of cells
derived from human tumors has been the subject of many studies. In the present study, this assay was
performed to measure the capability of each cell line to proliferate and produce colonies after
irradiation. This relationship can be modeled by a linear-quadratic function of radiation dose.
As is generally true for most glioma cell lines, the 9L cell line is aggressive and less
radiosensitive than other rat tumor cell lines (Bencokova et al. 2008; Henderson et al. 1981). It is the
most widely used of all rat brain tumor models for research (Barth 1998) as well as for preclinical
model used in brain radiotherapy (Vinchon-Petit et al. 2010); it has been utilized in such experiments
for more than 30 years (Kimler 1994). The MCF-7 cell line represents a well-adopted pre-clinical
model of breast tumor tissue. It has provided the basis of many breast cancer biology studies (Tutt et
al. 2006) and is relatively more radiosensitive (Matthews et al. 1989).
In the present study, we observed no difference between low dose rate 50 cGy/min and high
5 Gy/min dose rate survival curves of the 9L cell line (Figure 3A). Interestingly, we observed an
inverse dose rate effect for the MCF-7 cells (Figure 3B), where the lower dose rate of 50 cGy/min
induced a 50% increase in RBE compared to that for the reference 5 Gy/min dose rate. The inverse
dose rate effect is complemented with a linearization of the cell survival curve when the lower dose
rate experiment at 50 cGy/min is performed. The results observed above suggest that the optimum dose
rate radiotherapy can be significantly different depending on the tumor cells type.
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Several studies have shown that by decreasing the radiation dose rate, recovery processes are
allowed to take place during irradiation (i.e. within the first few hours), which usually leads to a
reduced biological effect (Hall 1972; Steel 1989). This traditional key characteristic of the dose-rate
effect appears to be inversed in this study. The mechanisms underlying the cause of the inverse nature
of the dose-rate effect are not well understood, but may be due to several reasons. Possible
explanations for this finding are that the effect is dependent on the intrinsic radiosensitivity that varies
along the cell cycle at the time of irradiation (Ling et al. 1995), cell type (Fertil and Malaise 1981),
doubling time (Mitchell et al. 1979a), cell age (Biade et al. 1997) and more clinically, the histology
type (Ramsay et al. 1992). Numerous studies have shown that the X-ray induced deficiency in DNA
synthesis depends on the cell cycle phase of cells at the time of irradiation (Denekamp 1986; Griffiths
et al. 1975; Rowley et al. 1985). In this study, the underlying mechanism leading to the 20% difference
in the efficacy between the treatments was (and still is) unclear. However these positive data warranted
the further exploration into identifying a mechanism that manifested as a dose-rate effect on the
biological effectiveness of megavoltage x-ray radiation doses on one of the cell lines investigated.
Radiation sensitivity, expressed as loss of reproductive ability, depends on the cell cycle phase
in which the cells are exposed. The variation in the cell cycle response to ionizing radiation is believed
to be due to the intrinsic radiosensitivity of some human tumor cells (Biade et al. 1997). A lower dose
rate would then be expected to be more effective if a phase of the cell cycle (i.e. G 2/M-phase) was
correlated with the radiosensitivity (Knox et al. 1993; Marples 2004; Wilson 2004). Numerous studies
have found that plateau-phase cultures are generally more radiosensitive than exponentially growing
cells. On the contrary, some studies have observed the development of radioresistance in plateau phase
with a V79 cells (Durand et al. 1973) and 9L cells (Kimler et al. 1982; Mendonca et al. 1989).
However, this condition is minimized in this study as our experiments were carried out with confluent
cultures, where the cell number remained constant throughout the irradiation.
The flow cytometry experiments performed as part of this work evaluated whether the
observed inverse dose-rate effect is linked to the differences in the intrinsic radiosensitivity between
these two cell lines. FACS analysis was performed to analyze the cell cycle distribution and DNA
content, indicated that the proportions of cells in the same phase were similar for the two cell lines.
Cells are most radiosensitive in phases G2/M, have intermediate radiosensitivity in G0/G1 and are most
radioresistant at the S-phase (Tubiana M et al. 1990). It is reasonable then to consider that the in vitro
radiosensitivity of a cell line may be influenced by the proportion of cells in the different phases of the
cell cycle. Our flow cytometry results indicate that the phase distribution of the cells most likely does
not play a significant role in the observed differences in the radiation sensitivities of the two cell lines.
This study has potential implications for external radiation delivery techniques, where the
dose-rate is greatly increased. It is hypothesized that in vitro cellular radiosensitivity is correlated with
in vivo tissue response (Deacon et al. 1984). For instance, the  parameter predicts best for intrinsic
radiosensitivity of tumor cells irradiated at a dose of 2 Gy (SF2) (Fertil and Malaise 1981; Malaise et
al. 1987). The clinical implementation of different dose-response parameters on biologically optimized
IMRT in breast cancer has been studied by Ferreira et al. (2008), which suggest that it can only be
maximized by predicting the individual patient radiosensitivity. In general, our study supports the view
that individualized radiation therapy may significantly increase the benefits for patients with extreme
radiosensitivity or radioresistance.
Since no single molecular factor has been identified that is common to all the cancer cell lines
that can explain their radiation sensitivity to radiation dose-rate, an improved understanding of the
intrinsic radiosensitivity and damage repair mechanisms should lead to personalized enhanced cancer
RT treatments. The results presented in this study may contribute to clinically significant
radiobiological effects as the lower dose-rate induced an increased cell killing in MCF-7 cells. It
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suggests that some patients with breast cancer would not benefit from the latest technological advances
and would better benefit from a dose delivery with a lower dose rate (rather than a higher) for a better
treatment outcome.
External beam conformal RT techniques such as 3D-CRT, IMRT, and VMAT have been
reviewed for partial breast irradiation (PBI) treatment (Njeh et al. 2012) and for malignant glioma of
the brain (Wagner et al. 2009). There are many papers in the literature showing that VMAT, which
enables the delivery of higher effective clinical dose-rates, can be the most efficient treatment option in
terms of plan quality and treatment time (better conformal dose distributions with fewer MUs).
Although VMAT offers the potential to provide improved target coverage and should be favored
because of the shorter treatment time compared to conventional RT techniques, in vitro experimental
evidence specific to VMAT and its optimization with the biological response of the tumor is lacking.
This is in agreement with the observation of McGarry et al. (2012) and Butterworth et al. (2012) by
addressing the difference in the spatio-temporal dose distribution on cell survival following exposure
to IMRT and VMAT. Therefore, as highlighted by these authors, there is a need for a definitive
radiobiological and clinical aspect for VMAT patient selection. Our data demonstrates that for certain
types of cancer cell lines a higher effective dose rate can lead to decreased radiobiological response
and therefore a less favorable treatment outcome. Hence, even for radiosensitive patients, a simpler
treatment technique (i.e 3D-CRT) is sufficient to maximize the outcome.
5. Conclusions
The data presented in this paper have focused on cell survival following the delivery of 10 MV X-rays
radiation doses at a dose-rate of 50 cGy/min compared to a 10-fold higher dose-rate of 5 Gy/min. To
date, there has been no literature published that investigates changes in the biological effectiveness of
10 MV X-ray radiation doses on 9L and MCF-7 cell lines with dose-rate. Our in vitro experiments
show that the lower dose rate induced a larger effect in cell killing in the MCF-7 cell line. This
observation emphasizes the importance of taking into account not only the physical dose but also the
radiobiological responses when planning a particular cancer treatment. This may help clinicians to
individualize patient treatment decisions so as to maximize the efficacy of treatment and hence the
clinical outcome of the RT treatment. Moreover, our results may provide important information to
predict whether all cancer patients, or perhaps only those with particular tumor types, since we have
demonstrated a variation in radiosensitivity, will benefit from advances in the technologies of RT that
enable the delivery of X-rays with high dose-rates. Understanding the molecular mechanisms leading
to cancer cell death induced by X-ray radiation at different dose rate may provide important
information to assist in the further development of novel treatment options in radiation therapy. Future
studies that need to be conducted are to evaluate radiation-induced damage and repair process in cancer
cells due to dose-rate effect.

Acknowledgements
The authors acknowledge the financial support from the National Health and Medical Research
Council (APP1084994).

Page 8 of 12

References
Barth R F. 1998. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2
(D74), RT-2 and CNS-1 gliomas. J Neurooncol 36:91-102.
Bencokova Z, Balosso J and Foray N. 2008. Radiobiological features of the anti-cancer strategies
involving synchrotron X-rays. J Synchrotron Radiat 15:74-85.
Benedict S H, Cardinale R M, Wu Q, Zwicker R D, Broaddus W C and Mohan R. 2001. Intensitymodulated stereotactic radiosurgery using dynamic micro-multileaf collimation. Int J Radiat
Oncol Biol Phys 50:751-8.
Biade S, Stobbe C C and Chapman J D. 1997. The intrinsic radiosensitivity of some human tumor cells
throughout their cell cycles. Radiat Res 147:416-21.
Butterworth K T, McGarry C K, Trainor C, McMahon S J, O'Sullivan J M, Schettino G, Hounsell A R
and Prise K M. 2012. Dose, dose-rate and field size effects on cell survival following exposure
to non-uniform radiation fields. Phys Med Biol 57:3197-206.
Chadwick K H and Leenhouts H P. 1973. A molecular theory of cell survival. Phys Med Biol 18:78-87.
Cheung K. 2006. Intensity modulated radiotherapy: advantages, limitations and future developments.
Biomed Imaging Interv J 2:e19.
Curtis S B. 1986. Lethal and potentially lethal lesions induced by radiation--a unified repair model.
Radiat Res 106:252-70.
Deacon J, Peckham M J and Steel G G. 1984. The radioresponsiveness of human tumours and the
initial slope of the cell survival curve. Radiother Oncol 2:317-23.
Denekamp J. 1986. Cell kinetics and radiation biology. Int J Radiat Biol Relat Stud Phys Chem Med
49:357-80.
Durand R E and Sutherland R M. 1973. Growth and radiation survival characteristics of V79-171b
Chinese hamster cells: a possible influence of intercellular contact. Radiat Res 56:513-27.
Ferreira B C, Mavroidis P, Adamus-Gorka M, Svensson R and Lind B K. 2008. The impact of different
dose-response parameters on biologically optimized IMRT in breast cancer. Phys Med Biol
53:2733-52.
Fertil B and Malaise E P. 1981. Inherent cellular radiosensitivity as a basic concept for human tumor
radiotherapy. Int J Radiat Oncol Biol Phys 7:621-9.
Fertil B and Malaise E P. 1985. Intrinsic radiosensitivity of human cell lines is correlated with
radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat
Oncol Biol Phys 11:1699-707.
Fowler J F, Welsh J S and Howard S P. 2004. Loss of biological effect in prolonged fraction delivery.
Int J Radiat Oncol Biol Phys 59:242-9.
Franken N A, Oei A L, Kok H P, Rodermond H M, Sminia P, Crezee J, Stalpers L J and Barendsen G
W. 2013. Cell survival and radiosensitisation: modulation of the linear and quadratic
parameters of the LQ model (Review). Int J Oncol 42:1501-15.
Franken N A, Rodermond H M, Stap J, Haveman J and van Bree C. 2006. Clonogenic assay of cells in
vitro. Nature protocols 1:2315-9.
Fu W, Dai J, Hu Y, Han D and Song Y. 2004. Delivery time comparison for intensity-modulated
radiation therapy with/without flattening filter: a planning study. Phys Med Biol 49:1535-47.
Furre T, Koritzinsky M, Olsen D R and Pettersen E O. 1999. Inverse dose-rate effect due to pre-mitotic
accumulation during continuous low dose-rate irradiation of cervix carcinoma cells. Int J
Radiat Biol 75:699-707.
Griffiths T D and Tolmach L J. 1975. Age-dependence of the x-ray-induced deficiency in DNA
synthesis in HeLa S3 cells during Generation 1. Radiat Res 63:501-30.
Hall E J. 1972. Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. Br J
Radiol 45:81-97.
Henderson S D, Kimler B F and Morantz R A. 1981. Radiation therapy of 9L rat brain tumors. Int J
Radiat Oncol Biol Phys 7:497-502.
Intensity Modulated Radiation Therapy Collaborative Working Group I. 2001. Intensity-modulated
radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 51:880-914.

Page 9 of 12

Kimler B F. 1994. The 9L rat brain tumor model for pre-clinical investigation of radiationchemotherapy interactions. J Neurooncol 20:103-9.
Kimler B F and Henderson S D. 1982. Cyclic responses of cultured 9L cells to radiation. Radiat Res
91:155-68.
Knox S J, Sutherland W and Goris M L. 1993. Correlation of tumor sensitivity to low-dose-rate
irradiation with G2/M-phase block and other radiobiological parameters. Radiat Res 135:2431.
Kragl G, af Wetterstedt S, Knausl B, Lind M, McCavana P, Knoos T, McClean B and Georg D. 2009.
Dosimetric characteristics of 6 and 10MV unflattened photon beams. Radiother Oncol 93:1416.
Lajtha L G and Oliver R. 1961. Some radiobiological considerations in radiotherapy. Br J Radiol
34:252-7.
Ling C C, Gerweck L E, Zaider M and Yorke E. 2010. Dose-rate effects in external beam radiotherapy
redux. Radiother Oncol 95:261-8.
Ling C C, Guo M, Chen C H and Deloherey T. 1995. Radiation-induced apoptosis: effects of cell age
and dose fractionation. Cancer Res 55:5207-12.
Lohse I, Lang S, Hrbacek J, Scheidegger S, Bodis S, Macedo N S, Feng J, Lutolf U M and Zaugg K.
2011. Effect of high dose per pulse flattening filter-free beams on cancer cell survival.
Radiother Oncol 101:226-32.
Malaise E P, Fertil B, Deschavanne P J, Chavaudra N and Brock W A. 1987. Initial slope of radiation
survival curves is characteristic of the origin of primary and established cultures of human
tumor cells and fibroblasts. Radiat Res 111:319-33.
Marples B. 2004. Is low-dose hyper-radiosensitivity a measure of G2-phase cell radiosensitivity?
Cancer Metastasis Rev 23:197-207.
Matthews J H, Meeker B E and Chapman J D. 1989. Response of human tumor cell lines in vitro to
fractionated irradiation. Int J Radiat Oncol Biol Phys 16:133-8.
McGarry C K, Butterworth K T, Trainor C, McMahon S J, O'Sullivan J M, Prise K M and Hounsell A
R. 2012. In-vitro investigation of out-of-field cell survival following the delivery of conformal,
intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT)
plans. Phys Med Biol 57:6635-45.
Mendonca M S, Rodriguez A and Alpen E L. 1989. Quiescence in 9L cells and correlation with
radiosensitivity and PLD repair. Radiat Res 117:433-47.
Mitchell J B and Bedford J S. 1977. Dose-rate effects in synchronous mammalian cells in culture. II. A
comparison of the life cycle of HeLa cells during continuous irradiation or multiple-dose
fractionation. Radiat Res 71:547-60.
Mitchell J B, Bedford J S and Bailey S M. 1979a. Dose-rate effects in mammalian cells in culture III.
Comparison of cell killing and cell proliferation during continuous irradiation for six different
cell lines. Radiat Res 79:537-51.
Mitchell J B, Bedford J S and Bailey S M. 1979b. Dose-rate effects in plateau-phase cultures of S3
HeLa and V79 cells. Radiat Res 79:552-67.
Moiseenko V, Duzenli C and Durand R E. 2007. In vitro study of cell survival following dynamic
MLC intensity-modulated radiation therapy dose delivery. Med Phys 34:1514-20.
Mu X, Lofroth P O, Karlsson M and Zackrisson B. 2003. The effect of fraction time in intensity
modulated radiotherapy: theoretical and experimental evaluation of an optimisation problem.
Radiother Oncol 68:181-7.
Njeh C F, Saunders M W and Langton C M. 2012. Accelerated partial breast irradiation using external
beam conformal radiation therapy: A review. Crit Rev Oncol Hematol 81:1-20.
Oktaria S, Corde S, Lerch M L, Konstantinov K, Rosenfeld A B and Tehei M. 2015. Indirect radiochemo-beta therapy: a targeted approach to increase biological efficiency of x-rays based on
energy. Phys Med Biol 60:7847-59.
Puck T T and Marcus P I. 1956. Action of x-rays on mammalian cells. J Exp Med 103:653-66.
Ramsay J, Ward R and Bleehen N M. 1992. Radiosensitivity testing of human malignant gliomas. Int J
Radiat Oncol Biol Phys 24:675-80.

Page 10 of 12

Rowley R and Leeper D B. 1985. Cell cycle age dependence for radiation-induced G2 arrest: evidence
for time-dependent repair. Radiat Res 103:326-36.
Siochi R A. 1999. Minimizing static intensity modulation delivery time using an intensity solid
paradigm. Int J Radiat Oncol Biol Phys 43:671-80.
Sorensen B S, Vestergaard A, Overgaard J and Praestegaard L H. 2011. Dependence of cell survival on
instantaneous dose rate of a linear accelerator. Radiother Oncol 101:223-5.
Stathakis S, Esquivel C, Gutierrez A, Buckey C R and Papanikolaou N. 2009. Treatment planning and
delivery of IMRT using 6 and 18MV photon beams without flattening filter. Appl Radiat Isot
67:1629-37.
Steel G G. 1989. Recovery kinetics deduced from continuous low dose-rate experiments. Radiother
Oncol 14:337-43.
Tubiana M, Dutreix J and A W (1990) Introduction to RadiobiologyTaylor & Francis.
Tubiana M and Eschwege F. 2000. Conformal radiotherapy and intensity-modulated radiotherapy-clinical data. Acta Oncol 39:555-67.
Tutt A and Yarnold J. 2006. Radiobiology of breast cancer. Clinical oncology 18:166-78.
Vinchon-Petit S, Jarnet D, Jadaud E, Feuvret L, Garcion E and Menei P. 2010. External irradiation
models for intracranial 9L glioma studies. J Exp Clin Cancer Res 29:142.
Vine K L, Locke J M, Ranson M, Pyne S G and Bremner J B. 2007. An investigation into the
cytotoxicity and mode of action of some novel N-alkyl-substituted isatins. Journal of
medicinal chemistry 50:5109-17.
Wagner D, Christiansen H, Wolff H and Vorwerk H. 2009. Radiotherapy of malignant gliomas:
comparison of volumetric single arc technique (RapidArc), dynamic intensity-modulated
technique and 3D conformal technique. Radiother Oncol 93:593-6.
Wang J Z, Li X A, D'Souza W D and Stewart R D. 2003. Impact of prolonged fraction delivery times
on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT). Int J
Radiat Oncol Biol Phys 57:543-52.
Wilson G D. 2004. Radiation and the cell cycle, revisited. Cancer Metastasis Rev 23:209-25.

Figure Captions:
Fig 1. Experimental setup for cellular irradiation.
Fig 2. Survival curves of 9L and MCF-7 irradiated at a dose-rate of 5 Gy/min. The data were fitted to
the linear-quadratic model. The error bars represent the means SEM of at least three independent
experiments.
Fig 3. Survival curves of 9L cells (Panel A) and MCF-7 cells (Panel B) irradiated at dose rate of 50
cGy/min vs. dose rate 5 Gy/min. The data were fitted to the linear quadratic model. Each data point
represents the means SEM of at least three independent experiments (each triplicate).
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Table 1. Summary of cell survival parameters
Cell line

Dose rate (Gy/min)

 (Gy-1)

 (Gy-2)

9L

0.5

0.20 0.04

0.013 0.008

5

0.20 0.06

0.013 0.008

0.5

0.83 0.01
0.47 0.03

0.00
0.040 0.007

MCF-7

5

Table 2. Summary of cell cycle distribution of unirradiated confluent cell populations
Cell line
9L
MCF-7

G0/G1 (%)
64.2
58.7

S (%)
12.6
13.2

G2/M (%)
23.2
28.1

Highlights







We examined the biological effect of differing dose-rates for 10 MV from a LINAC.
Cell survival curves were used to determine the and values (radiosensitivity).
A reduction in dose rate has no effect on the survival curve of 9L cells. 
A lower dose rate killed more MCF-7 cells. 
We showed that dose-rate is important in determining the efficacy of IMRT.
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